Durvalumab plus bevacizumab, added to TACE, shows benefit for unresectable hepatocellular carcinoma
Durvalumab plus bevacizumab, added to TACE, shows benefit for unresectable hepatocellular carcinoma
What is new for treatment of soft tissue and bone sarcomas?
Cancer personomics: Launching the missile - Localised endometrial carcinoma.
Novel therapies and combinations in ovarian cancer
What's new on ADCs in management of advanced NSCLC
Treatment of metastatic NSCLC without PD-L1 expression and without oncogene addiction
Personalised systemic treatment in advanced prostate cancer
Multiple myeloma treatment in Dakar: Epidemiological, diagnostic, and therapeutic aspects
Nivolumab plus ipilimumab improves on chemo in previously untreated MSI-H/dMMR mCRC
The role of nurses in the fight against cervical cancer in Cameroon
Development of AORTIC oncology nursing competencies in sub-Sahran Africa
Gastro-intestinal endoscopy capacity in Nigeria: strengths and challenges